Russell Won, MD
General Practice · Saint Louis, MONPI 1245327725
Payments from drug & device makers
Across 65 payments — averaging $39.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$503
- Novo Nordisk$434
- AstraZeneca$406
- Procept Biorobotics Corporation$157
- Amgen$139
- Sumitomo Pharma America, Inc.$125
- plus $772 from 12 others
What the payments were for
- Speaking & faculty fees$1255%
- Food & beverage$2,40495%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 5 | $503 |
| Novo Nordisk | 15 | $434 |
| AstraZeneca | 5 | $406 |
| Procept Biorobotics Corporation | 1 | $157 |
| Amgen | 1 | $139 |
| Sumitomo Pharma America, Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $116 |
| Johnson & Johnson | 7 | $92 |
| Novartis | 6 | $83 |
| Sunovion Pharmaceuticals Inc. | 6 | $78 |
| AbbVie(2 entities) | 4 | $76 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Amarin Pharma, Inc. | 3 | $55 |
| Lilly USA, LLC | 3 | $39 |
| Exact Sciences | 1 | $28 |
| Pfizer | 1 | $14 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,536 in reported general payments places this provider in the 90th percentile of 1,446 general practice providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 512 | $233,130 |
| OzempicSemaglutide | 39 | $53,434 |
| JanuviaSitagliptin Phosphate | 89 | $49,760 |
| JardianceEmpagliflozin | 108 | $48,516 |
| XareltoRivaroxaban | 64 | $38,461 |
| MyrbetriqMirabegron | 87 | $29,887 |
| TradjentaLinagliptin | 39 | $28,314 |
| EntrestoSacubitril/Valsartan | 93 | $26,253 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 81 | $24,532 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $21,157 |
| FarxigaDapagliflozin Propanediol | 33 | $18,220 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $18,011 |
| Atorvastatin Calcium | 1,349 | $17,972 |
| TrulicityDulaglutide | 17 | $17,102 |
| LinzessLinaclotide | 27 | $15,537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $233,130512 claims |
| GSKArexvy, Anoro Ellipta, Trelegy Ellipta, Breo Ellipta | $503 | $75,469168 claims |
| Novo NordiskOzempic | $434 | $53,43439 claims |
| Johnson & JohnsonXarelto | $92 | $38,46164 claims |
| Astellas Pharma US IncMyrbetriq | $11 | $29,88787 claims |
| NovartisEntresto | $83 | $26,25393 claims |
| AstraZenecaFarxiga, Brilinta | $406 | $25,02259 claims |
| Lilly USA, LLCTrulicity | $39 | $17,10217 claims |
| AbbVieLinzess | $76 | $15,53727 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $125 | $6,09825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,446 general practice providers in Missouri.
Other general practice in Saint Louis
- Bernard MillerSaint Louis$546K
- Shuka MoshiriSaint Louis$253K
- Rex HudsonSaint Louis$49K
- Nadeemuddin QureshiSaint Louis$22K
- Sable MunteanSaint Louis$16K
- Johnathan MillerSaint Louis$13K
- Jason AllenSaint Louis$11K
- Jeffrey SindelarSaint Louis$9K
- William WhitsonSaint Louis$6K
- Mark HeskerSaint Louis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.